Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
24 hedge funds and large institutions have $14.1M invested in Astria Therapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
17% more capital invested
Capital invested by funds: $12.1M → $14.1M (+$2M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.14% less ownership
Funds ownership: 0.59% → 0.45% (-0.14%)
4% less funds holding
Funds holding: 25 → 24 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$806K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$471K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$235K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.5K |
| 5 |
Bank of New York Mellon
New York
|
+$23.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$1.24M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$489K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$168K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$94K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
26
A.R.T. Advisors
New York
| – | -$94K | -1,057 | Closed |
|
|
OAM
27
Oxford Asset Management
Oxford,
United Kingdom
| – | -$29K | -329 | Closed |
|
28
Goldman Sachs
New York
| – | -$24K | -273 | Closed |
|
29
Acadian Asset Management
Boston,
Massachusetts
| – | -$24K | -272 | Closed |
|
30
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -87 | Closed |
|
|
CHP
31
Cable Hill Partners
Portland,
Oregon
| – | -$1K | -8 | Closed |
|
ATXS Hedge Fund Activity: Q1 2018 in Review
24 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2018, worth a combined $14.1M — up 17% from $12.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATXS and 6 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $806K. The largest seller was Clarus Ventures, cutting an estimated $1.24M.
- 24 institutional investors held Astria Therapeutics (ATXS) as of Q1 2018, down from 25 in Q4 2017.
- Funds reported $14.1M of Astria Therapeutics stock for Q1 2018, up 17% quarter-over-quarter.
- 6 funds opened new Astria Therapeutics positions in Q1 2018 and 7 closed out, a net change of -1 holder.
- The largest Astria Therapeutics buyer in Q1 2018 was Renaissance Technologies, an estimated $806K added.
- The largest Astria Therapeutics seller in Q1 2018 was Clarus Ventures, an estimated $1.24M sold.
Based on aggregated 13F filings for Q1 2018.